ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

DCT Board To Consider RFA for Clinical R01 Grants At Next Meetings

January 21, 1994

CAP, ASCCP Recommendations Standardize Lesion Terminology

July 27, 2012

Upton Finds Work For Former Division, Program Directors

September 14, 1979

Cooperative Groups Fight to Keep CGOP Alive As DCPC, DCT Argue Over Who Pays

July 11, 1986

Yarbro Refuses To Seek Core Renewal, Quits Director Post

September 22, 1978

NCI Intramural Research: More Than 200 Scientists At Frederick To Become NCI Employees This Year

March 26, 1999